Wildpixel | Istock | Getty images
A version of this article appeared for the first time in the Healthy Bulletin returns from CNBC, which brings the latest medical care news directly to its entrance tray. Subscribe here To receive future editions.
A universal cancer vaccine, which once seemed an impossible dream, may be advancing closer to becoming a reality.
On Friday, researchers from the University of Florida said that the findings of a new study could lead to the development of a universal shot that can boost the immune system to combat cancer. The study in mice, published in Nature's biomedical engineering, showed that an experimental MRNA vaccine increased the tumor struggle effects of a common cancer drug called immune control point inhibitors.
The vaccine is not designed for a specific cancer virus or cells, but is designed to “arouse” the immune system against the disease “, which drives it to respond as if it fought against a virus,” according to a UF release.
“What we find is through the use of a vaccine designed not to point to cancer specifically, but to stimulate a strong immune response, we could cause a very strong anti -cancer reaction,” said Dr. Duane Mitchell, co -author of the study and professor of neurosurgery at the University Medicine Faculty, in the statement.
That is different from the current approaches to cancer vaccines, which involve finding an objective expressed by many cancer patients or, in the case of Modern and MerckPersonalized vaccine development adapted to the specific tumor of each patient.
The universal vaccine has the potential to be widely used between cancer patients, “even possibly leads us to a standard cancer vaccine,” Mitchell said.
UF researchers are still working to replicate the findings in humans. If they do, a unique vaccine for everyone could provide an alternative to surgery, radiation and chemotherapy.
This is how the vaccine works: RNM's shot essentially tells the body to produce certain proteins that stimulate the immune system, including one called PD-L1, which is often found on the surface or inside the cancer cells. These cells often use PD-L1 to hide from immune attacks.
But by increasing PD-L1, the vaccine can cause tumors to be more vulnerable to immune control point inhibitors who block that protein, which helps the immune system recognize and destroy cancer.
The study showed promising results in tumors resistant to treatment in skin cancers when combining the HRNM vaccine with a monoclonal antibody, a drug of common immunotherapy that tries to alert the immune system that a tumor is strange and must be attacked.
He also showed positive results when analyzed in the mouse skin, bone and brain cancers such as solo treatment. In some cases, tumors were completely eliminated.
“This document describes a very unexpected and exciting observation: that even a non -specific vaccine for any particular tumor or virus, whenever it is an RNM vaccine, could lead to specific tumor effects,” said Senior author Dr. Elias Sayour, a pediatric oncologist at UF Health, in a release.
Do not hesitate to send any advice, suggestion, stories ideas and data to Annika in [email protected].
The latest in medical care technology: the digital health gains season is approaching, this is what you should see
We are just a few days from the top of the digital health profit season, and this quarter will surely be interesting.
The two companies that were made public earlier this year, Hinge Health and Viath Health, will inform the results for the first time from their debut. And since the Tax and Expenses Bill of President Donald Trump was approved and his rate deadline on August 1 is approaching, we will obtain an idea of how digital health companies have been operating against a volatile curtain of macroeconomic and political background.
These are some of the reports that CNBC will be watching:
Hinge health – August 5
- The digital physiotherapy company Hinge Health will publish its profits from the second quarter on August 5, its first report from its debut in the New York Stock Exchange in May. Hinge's shares opened to $ 39.25 on May 22, and are negotiated above $ 46 from intradic negotiation on Wednesday. During his first quarter of this year, Hinge said that revenues increased 50% to $ 123.8 million, above $ 82.7 million during the same period last year, and that net income for the period was $ 17.1 million compared to a loss of $ 26.5 million a year ago.
Voting health – August 7
- The virtual chronic attention company Health will report the results of the second quarter on August 7, which will be the first time that the company revealed finance since its debut in June at Nasdaq. Voted shares opened to $ 23 on June 6, and about $ 19 are negotiated from intra -established negotiation on Wednesday. Voting revenues increased 57% in their first quarter to $ 55 million of $ 35.1 million a year before, according to their prospect.
Hims and his health – August 4
- Telehealth Company Hims & Hers Health reports results in the second quarter on August 4, and executives will probably face questions about their short collaboration with Novo Nordisk. In April, Novo Nordisk said he would offer Wagovy through several Telesalud companies, including Hims & Hers, to expand access to great -success weight loss injection. But at the end of June, the agreement collapsed on the sale of Hims & Hers and the promotion of cheaper imitations. The Hims & Hers' actions had shot more than 100% this year since intradic negotiation on Wednesday.
Duration – August 7
- Dxxxity, a digital platform for medical professionals, was one of the few 2024 stars when the company's price of the shares doubled. Investors will observe closely to see if the company can maintain its impulse when it reports the results of the first quarter of the first 2026 quarter of the fiscal year on August 7.
Teradoc health – July 29
- The CEO of Teladoc Health, Chuck Divita, has been working to convert the high -flight virtual care company after four quarters of decreased income and a prolonged drop in the price of shares. The company will publish results in the second quarter on July 29. Teradoc's shares have dropped more than 4% to date until Wednesday's intradic negotiation.
We will have a lot to immerse yourself in the coming weeks, so be sure to keep up with the CNBC coverage.
Do not hesitate to send any advice, suggestion, stories ideas and data to Ashley at [email protected].
